Astellas Pharma Inc. spinout Cardeus Pharmaceuticals Inc.'s COX-1 inhibitor tamps down neuroinflammation in the brain and could be synergistic with other treatments to keep dementia associated with diseases like Parkinson's in check.

Activation of microglial cells in the brain leads to neuroinflammation and neurodegeneration in Parkinson's disease (PD) and Huntington's disease (HD).